EFFICACY AND SAFETY OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR WITHIN EARLY ACCESS PROGRAM IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: SVRW12 ANALISYS

被引：0
|
作者：
Calleja, J. L.
Ruiz, B.
Pascasio, J. M.
Gea, F.
Barcena, R. [1 ]
Larrubia, J. R. [2 ]
Forns, X.
Alvarez, R.
Sola, R.
Romero, M.
Sancho, A.
Salcedo, I.
Fernandez, M. J.
机构：
[1] Univ Hosp Ramon & Cajal, Madrid, Spain
[2] Univ Hosp Guadalajara, Guadalajara, Jalisco, Mexico
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2013年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：32 / 33
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of grazoprevir plus ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection
    Gane, E.
    Ben Ari, Z.
    Mollison, L.
    Zuckerman, E.
    Bruck, R.
    Baruch, Y.
    Howe, A. Y. M.
    Wahl, J.
    Bhanja, S.
    Hwang, P.
    Zhao, Y.
    Robertson, M. N.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (10) : 789 - 797
  • [32] Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
    Manns, Michael P.
    McCone, Jonathan, Jr.
    Davis, Mitchell N.
    Rossaro, Lorenzo
    Schiff, Eugene
    Shiffman, Mitchel L.
    Bacon, Bruce
    Bourliere, Marc
    Sulkowski, Mark S.
    Bruno, Savino
    Balart, Luis
    Bronowicki, Jean-Pierre
    Kwo, Paul
    Poordad, Fred
    Felizarta, Franco
    Reddy, K. Rajender
    Helmond, Frans A.
    Sings, Heather L.
    Pedicone, Lisa D.
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Vierling, John M.
    LIVER INTERNATIONAL, 2014, 34 (05) : 707 - 719
  • [33] Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaiVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment
    Moog, Gero
    Mauss, Stefan
    Hueppe, Dietrich
    Spengler, Ulrich
    Schott, Eckart
    Eisenbach, Christoph
    Schober, Andreas
    Heyne, Renate
    Jung, Maria-Christina
    Teuber, Gerlinde
    Doss, Margareta Frank
    Roessle, Martin
    Pape, Stefan
    Schuchmann, Marcus
    Alshuth, Ulrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2013, 144 (05) : S982 - S983
  • [34] cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients
    Turnes, Juan
    Oyagueez, Itziar
    Planas, Ramon
    Garcia-Samaniego, Javier
    Diago, Moises
    Crespo, Javier
    Luis Calleja, Jose
    Sola, Ricard
    Casado, Miguel A.
    Romero-Gomez, Manuel
    HEPATOLOGY, 2013, 58 : 1107A - 1108A
  • [35] OLDER AGE INCREASES THE RISK OF RELAPSE IN GENOTYPE-1 CHRONIC HEPATITIS C PATIENTS SHOWING COMPLETE EARLY VIROLOGIC RESPONSE DURING PEGINTERFERON AND RIBAVIRIN THERAPY
    Borroni, Gianmario
    Andreoletti, Marco
    Bortoli, Aurora
    Casiraghi, Maria Antonietta
    Cazzaniga, Massimo
    Ceriani, Roberto
    Guerzoni, Patrizia
    Mandelli, Giovanna
    Omazzi, Barbara
    Pich, Maria Gioia L.
    Prada, Alberto
    Spinzi, Giancarlo
    Terreni, Natalia M.
    HEPATOLOGY, 2010, 52 (04) : 809A - 809A
  • [36] Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study
    Moog, Gero
    Mauss, Stefan
    Hueppe, Dietrich
    Spengler, Ulrich
    Schott, Eckart
    Eisenbach, Christoph
    Schober, Andreas
    Heyne, Renate
    Jung, Maria-Christina
    Teuber, Gerlinde
    Doss, Margareta Frank
    Roessle, Martin
    Pape, Stefan
    Schuchmann, Marcus
    Alshuth, Ulrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2013, 144 (05) : S980 - S980
  • [37] EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C
    Poordad, F.
    Lawitz, E.
    Pozza, R.
    Shiffman, M.
    Bacon, B.
    Godofsky, E.
    Halliman, D.
    Heise, J.
    Chun, E.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
  • [38] The relative efficacy and safety of simeprevir-based triple therapy compared to boceprevir and telaprevir in treatment naive patients chronically infected with genotype-1 hepatitis C virus: Bayesian network meta-analyses
    Bryden, Peter A.
    Quigley, Joan M.
    Padhiar, Amie
    Cerri, Karin
    Scott, David A.
    HEPATOLOGY, 2013, 58 : 756A - 756A
  • [39] Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin
    Snoeck, Eric
    Hadziyannis, Stephanos J.
    Puoti, Claudio
    Swain, Mark G.
    Berg, Thomas
    Marcellin, Patrick
    Zarski, Jean-Pierre
    Jorga, Karin
    Zeuzem, Stefan
    LIVER INTERNATIONAL, 2008, 28 (01) : 61 - 71
  • [40] Efficacy and safety of telaprevir-based triple therapy for patients aged 66 years and older with genotype 1b chronic hepatitis C
    Yamagiwa, Satoshi
    Ishikawa, Toru
    Tsubata, Shunsuke
    Waguri, Nobuo
    Sugitani, Soichi
    Wakabayashi, Hiroto
    Takamura, Masaaki
    Igarashi, Masato
    Nomoto, Minoru
    HEPATOLOGY, 2014, 60 : 691A - 692A
12345